Aurélie bertaut

Head of methodology and biostatistic unit

Centre Georges-François Leclerc

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Aurélie Bertaut is the Head of the Methodology and Biostatistics Unit at the Centre Georges-François Leclerc in France. Her research interests include the evaluation of biomarkers in cancer, particularly focusing on sarcoma and pancreatic cancer, as well as the impact of treatment on quality of life in oncology patients. She has contributed to multiple studies involving immunotherapy, chemotherapy regimens, and data mining tools to enhance cancer research.

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (3)

Xavier Durando

PU-PH Head of oncology department Clinical Research Director

FRANCE

View details

Emmanuel Desandes

Paris university

FRANCE

View details

Masayuki Ohtsuka

Chiba University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Aurélie bertaut

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Small Extracellular Vesicles as Biomarkers in Sarcoma Follow-Up: Protocol for a Prospective, Multicentric Pilot Study

Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research

Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer

Response to Sorscher

Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation

Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions

Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma

Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies

Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer

Collaborators (3)

Xavier Durando

Emmanuel Desandes

Masayuki Ohtsuka

Make your next move.